BeOne Medicines (NASDAQ:ONC) Price Target Raised to $410.00

BeOne Medicines (NASDAQ:ONC) had its price target lifted by Guggenheim from $400.00 to $410.00 in a research note published on Friday,Benzinga reports. Guggenheim currently has a buy rating on the stock.

A number of other equities analysts have also commented on ONC. Jefferies Financial Group reissued a “buy” rating and issued a $420.00 price target on shares of BeOne Medicines in a report on Monday, November 17th. Royal Bank Of Canada upped their target price on shares of BeOne Medicines from $417.00 to $425.00 and gave the stock an “outperform” rating in a research report on Thursday. Weiss Ratings restated a “sell (d-)” rating on shares of BeOne Medicines in a research report on Wednesday, January 21st. Citizens Jmp lifted their price target on BeOne Medicines from $348.00 to $396.00 and gave the stock a “market outperform” rating in a research note on Friday, November 7th. Finally, Truist Financial set a $400.00 price objective on BeOne Medicines in a report on Monday, November 24th. Twelve equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, BeOne Medicines currently has an average rating of “Moderate Buy” and a consensus price target of $394.25.

BeOne Medicines Price Performance

Shares of NASDAQ ONC opened at $316.99 on Friday. The stock’s 50-day simple moving average is $336.81 and its two-hundred day simple moving average is $330.87. BeOne Medicines has a twelve month low of $196.45 and a twelve month high of $385.22. The firm has a market capitalization of $34.76 billion, a P/E ratio of 125.79 and a beta of 0.53. The company has a quick ratio of 2.17, a current ratio of 2.39 and a debt-to-equity ratio of 0.03.

BeOne Medicines (NASDAQ:ONC) last issued its quarterly earnings data on Thursday, February 26th. The company reported $0.58 EPS for the quarter, missing the consensus estimate of $1.60 by ($1.02). The business had revenue of $1.50 billion for the quarter, compared to analysts’ expectations of $1.45 billion. BeOne Medicines had a return on equity of 11.10% and a net margin of 5.37%. As a group, equities analysts anticipate that BeOne Medicines will post -5.82 EPS for the current fiscal year.

Insider Activity

In other news, SVP Chan Henry Lee sold 1,660 shares of the business’s stock in a transaction dated Wednesday, February 4th. The stock was sold at an average price of $349.52, for a total value of $580,203.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO John Oyler sold 75,631 shares of the firm’s stock in a transaction that occurred on Monday, December 15th. The stock was sold at an average price of $307.79, for a total value of $23,278,465.49. Following the transaction, the chief executive officer owned 24,369 shares in the company, valued at approximately $7,500,534.51. The trade was a 75.63% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 102,656 shares of company stock worth $31,567,496. Company insiders own 6.62% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. EFG International AG purchased a new stake in BeOne Medicines during the 4th quarter valued at $25,000. Anchor Investment Management LLC bought a new position in shares of BeOne Medicines during the second quarter valued at about $26,000. Leonteq Securities AG bought a new position in shares of BeOne Medicines during the fourth quarter valued at about $35,000. Daiwa Securities Group Inc. purchased a new stake in shares of BeOne Medicines during the second quarter worth about $35,000. Finally, CWM LLC grew its stake in shares of BeOne Medicines by 32.8% in the fourth quarter. CWM LLC now owns 158 shares of the company’s stock worth $48,000 after purchasing an additional 39 shares during the last quarter. 48.55% of the stock is owned by hedge funds and other institutional investors.

More BeOne Medicines News

Here are the key news stories impacting BeOne Medicines this week:

• Positive Sentiment: Analysts raised price targets — Truist boosted its target to $412 (buy), implying ~30% upside from the cited reference price. Benzinga
• Positive Sentiment: Guggenheim raised its target to $410 (buy), signaling similar upside (~29%). Benzinga
• Positive Sentiment: Barclays raised its target to $405 and kept an overweight rating, another vote of confidence from sell‑side analysts. Benzinga
• Neutral Sentiment: Revenue beat — Q4 revenue was $1.50B vs. consensus ~$1.45B, showing top‑line strength even as other metrics disappointed. Earnings Presentation
• Neutral Sentiment: Analyst/coverage writeups and Q4 metric breakdowns are available (Zacks, Seeking Alpha, Yahoo) for investors wanting full detail on margins, ROE and segment performance. Zacks Analysis Yahoo
• Neutral Sentiment: Reported short‑interest data in the feed shows zero/NaN values and a 0.0 days‑to‑cover ratio — likely data reporting issues rather than a meaningful change in short activity.
• Negative Sentiment: Large EPS miss — Q4 EPS of $0.58 missed consensus ~$1.60 by ~$1.02, a key negative that pressured sentiment despite revenue strength. (See Q4 results commentary.)
• Negative Sentiment: Disappointing FY2026 guidance — company issued revenue guidance of ~$6.2–6.4B vs. consensus ~6.5B, which the market viewed as conservative and has weighed on the stock. Investing.com
• Negative Sentiment: Coverage/articles highlight the post‑earnings selloff and investor reassessment after the EPS miss and guidance gap. YicaiGlobal

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.